The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Operating Characteristics of Prostate-Specific Antigen in Men With an Initial PSA Level of 3.0 ng/mL or Lower
Abstract
CONTEXT: Three fourths of US men older than 50 years have been screened with prostate-specific antigen (PSA) for prostate cancer. OBJECTIVE: To estimate the receiver operating characteristic (ROC) curve for PSA. DESIGN, SETTING, AND PARTICIPANTS: Calculation of PSA ROC curves in the placebo group of the Prostate Cancer Prevention Trial, a randomized, prospective study conducted from 1993 to 2003 at 221 US centers. Participants were 18 882 healthy men aged 55 years or older without prostate cancer and with PSA levels less than or equal to 3.0 ng/mL and normal digital rectal examination results, followed up for 7 years with annual PSA measurement and digital rectal examination. If PSA level exceeded 4.0 ng/mL or rectal examination result was abnormal, a prostate biopsy was recommended. After 7 years of study participation, an end-of-study prostate biopsy was recommended in all cancer-free men. MAIN OUTCOME MEASURES: Operating characteristics of PSA for prostate cancer detection, including sensitivity, specificity, and ROC curve. RESULTS: Of 8575 men in the placebo group with at least 1 PSA measurement and digital rectal examination in the same year, 5587 (65.2%) had had at least 1 biopsy; of these, 1225 (21.9%) were diagnosed with prostate cancer. Of 1213 cancers with Gleason grade recorded, 250 (20.6%) were Gleason grade 7 or greater and 57 (4.7%) were Gleason grade 8 or greater. The areas under the ROC curve (AUC) for PSA to discriminate any prostate cancer vs no cancer, Gleason grade 7 or greater cancer vs no or lower-grade cancer, and Gleason grade 8 or greater cancer vs no or lower-grade cancer were 0.678 (95% confidence interval [CI], 0.666-0.689), 0.782 (95% CI, 0.748-0.816), and 0.827 (95% CI, 0.761-0.893), respectively (all P values <.001 for AUC vs 50%). For detecting any prostate cancer, PSA cutoff values of 1.1, 2.1, 3.1, and 4.1 ng/mL yielded sensitivities of 83.4%, 52.6%, 32.2%, and 20.5%, and specificities of 38.9%, 72.5%, 86.7%, and 93.8%, respectively. Age-stratified analyses showed slightly better performance of PSA in men younger than 70 years vs those 70 years or older with AUC values of 0.699 (SD, 0.013) vs 0.663 (SD, 0.013) (P = .03). CONCLUSION: There is no cutpoint of PSA with simultaneous high sensitivity and high specificity for monitoring healthy men for prostate cancer, but rather a continuum of prostate cancer risk at all values of PSA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sampling-based approaches to calculating marginal densities
Gelfand, A. E., & Smith, A. F. M. (1990) · Journal of the American Statistical Association · doi:10.1080/01621459.1990.10476213 · Cited by 6,606
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Self-citationSathianathen, N. (2021) · 50 Studies Every Urologist Should Know · doi:10.1093/med/9780190655341.003.0002 · Cited by 2,080
Phases of Biomarker Development for Early Detection of Cancer
Pepe, M. S., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M., & Yasui, Y. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1054 · Cited by 1,686 · cited 3×
“Funding/Support: This study was supported in part by Public Health Service grants CA 37429, CA 35178, CA 45808, and CA 86402 from the National Cancer Institute.”
MethodInfluentialCatalona, W. J. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510080052031 · Cited by 998
Weir, H. K. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg040 · Cited by 867
Assessment of diagnostic tests when disease verification is subject to selection bias
Begg, C. B., & Greenes, R. A. (1983) · Biometrics · doi:10.2307/2530820 · Cited by 708 · cited 1×
“A confirmatory ROC analysis for prostate cancer vs no prostate cancer was performed by adding unverified participants to biopsy-verified participants and using a verification bias adjustment.(15,16) To perform the adjustment, a Markov Chain Monte Carlo algorithm using the covariates age, family history of prostate can…”
MethodClegg, L. X., Li, F. P., Hankey, B. F., Chu, K., & Edwards, B. K. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.17.1985 · Cited by 535
Quinn, M., & Babb, P. (2002) · BJU International · doi:10.1046/j.1464-410x.2002.2822.x · Cited by 446
Sirovich, B. E., Schwartz, L. M., & Woloshin, S. (2003) · JAMA · doi:10.1001/jama.289.11.1414 · Cited by 369
Cited by
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00459 · Cited by 2,522
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
The International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN), Harley, J. B., Alarcón-Riquelme, M. E., Criswell, L. A., Jacob, C. O., Kimberly, R. P., Moser, K. L., Tsao, B. P., Vyse, T. J., & Langefeld, C. D. (2008) · Nature Genetics · doi:10.1038/ng.81 · Cited by 1,309
“This value is comparable to that of other diagnostic tests, such as the prostate-specific antigen for prostate cance”
ResultAssessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
Thompson, I. M., Ankerst, D. P., Chi, C., Goodman, P. J., Tangen, C. M., Lucia, M. S., Feng, Z., Parnes, H. L., & Coltman, C. A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj131 · Cited by 938
Self-citationProstate-specific antigen and prostate cancer: prediction, detection and monitoring
Lilja, H., Ulmert, D., & Vickers, A. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2351 · Cited by 921
American Cancer Society Guidelines for the Early Detection of Cancer, 2006
Smith, R. A., Cokkinides, V., & Eyre, H. J. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.1.11 · Cited by 639
Tumor-induced anorexia and weight loss are mediated by the TGF-β superfamily cytokine MIC-1
Johnen, H., Lin, S., Kuffner, T., Brown, D. A., Tsai, V. W.-W., Bauskin, A. R., Wu, L., Pankhurst, G., Jiang, L., Junankar, S., et al. (2007) · Nature Medicine · doi:10.1038/nm1677 · Cited by 612
Screening tests: a review with examples
Maxim, L. D., Niebo, R., & Utell, M. J. (2014) · Inhalation Toxicology · doi:10.3109/08958378.2014.955932 · Cited by 562
Carter, H. B., Ferrucci, L., Kettermann, A., Landis, P., Wright, E. J., Epstein, J. I., Trock, B. J., & Metter, E. J. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj410 · Cited by 556
Prostate Specific Antigen Best Practice Statement: 2009 Update
Greene, K. L., Albertsen, P. C., Babaian, R. J., Carter, H. B., Gann, P. H., Han, M., Kuban, D. A., Sartor, A. O., Stanford, J. L., Zietman, A., et al. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.07.093 · Cited by 517
Pokorny, M. R., de Rooij, M., Duncan, E., Schröder, F. H., Parkinson, R., Barentsz, J. O., & Thompson, L. C. (2014) · European Urology · doi:10.1016/j.eururo.2014.03.002 · Cited by 503
Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer
Thompson, I. M., Chi, C., Ankerst, D. P., Goodman, P. J., Tangen, C. M., Lippman, S. M., Lucia, M. S., Parnes, H. L., & Coltman, C. A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj307 · Cited by 323
Self-citationGenetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies
Harley, I. T. W., Kaufman, K. M., Langefeld, C. D., Harley, J. B., & Kelly, J. A. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2571 · Cited by 297
A Risk-Based Strategy Improves Prostate-Specific Antigen–Driven Detection of Prostate Cancer
Roobol, M. J., Steyerberg, E. W., Kranse, R., Wolters, T., van den Bergh, R. C. N., Bangma, C. H., & Schröder, F. H. (2010) · European Urology · doi:10.1016/j.eururo.2009.08.025 · Cited by 286
Pepe, M. S., Fan, J., Feng, Z., Gerds, T., & Hilden, J. (2015) · Statistics in Biosciences · doi:10.1007/s12561-014-9118-0 · Cited by 191
“An example of a biomarker with this sort of predictive power is prostate specific antigen [19], one of the few cancer biomarkers currently used in cancer screening.”
Metadata
- Authors
- Thompson, I. M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2005-07-06
- Volume
- 294
- Issue
- 1
- Pages
- 66
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1978177793
- Cited by
- 704
- References
- 20
- FWCI
- 43.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.